 Home > Active Ingredient News > Blood System > JCO: Brentuximab Vedotin can significantly reduce the dose of radiotherapy in children with high-risk HL without affecting the efficacy

JCO: Brentuximab Vedotin can significantly reduce the dose of radiotherapy in children with high-risk HL without affecting the efficacy

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

label

high c4a

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The long-term event-free survival rate of pediatric patients with Hodgkin’s lymphoma (HL) using combination therapy is close to 90%, and the overall survival rate (OS) can reach 98%-99%.

Lymphoma

Brentuximab vedotin (Brentuximab vedotin) is an effective anti-CD30 antibody-drug conjugate, which has been approved for adult classic Hodgkin's lymphoma.

child

This study is an open-label, single-arm, multi-center first-line clinical trial, recruiting stage IIB, IIIB, or IV stage HL children (≤18 years old) with classic HL, aiming to evaluate whether Bentuximab is available To reduce the dose of radiotherapy in children and adolescents with classic Hodgkin’s lymphoma.

According to GPOH-HD2002 treatment group 3 (TG3), in OEPA/COPDac (vincristine, etoposide, prednisone and adriamycin/cyclophosphamide, vincristine, prednisone and dacarbazine) regimen In, vincristine was replaced with brentuximab vedodine; two courses of AEPA and 4 courses of CAPDAC.

In total, 77 patients were recruited, of which 27 (35%) achieved complete remission at ERA and did not receive radiation therapy.

3 years EFS and OS

The median follow-up time was 3.

The combination of Bentuximab and Vidotin is highly tolerated as the first-line treatment of children with high-risk HL, which can significantly reduce the exposure to radiotherapy, and can obtain good curative effect.

Original source:

Metzger Monika L, Link Michael P, Billett Amy L et al.

org/10.
1200/JCO.
20.
03286" target="_blank" rel="noopener">Excellent Outcome for Pediatric Patients With High- Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$200-250/G FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.